Selected article for: "HBsAg antigen surface and surface antigen"

Author: Zhao, Nan; Ma, Yao; Zhang, Shengmei; Fang, Xin; Liang, Zhenglun; Liu, Gang
Title: New muramyl dipeptide (MDP) mimics without the carbohydrate moiety as potential adjuvant candidates for a therapeutic hepatitis B vaccine (HBV)
  • Cord-id: 5tgr9p2f
  • Document date: 2011_7_15
  • ID: 5tgr9p2f
    Snippet: A series of new muramyl dipeptide (MDP) mimics were designed and synthesized via a solid-phase synthetic route. Their adjuvant activities were evaluated ex vivo for investigation of the synergism of the S(28–39) peptide, which is an MHC class I binding epitope of recombinant hepatitis B surface antigen (HBsAg) for both humans and mice. Several compounds without the carbohydrate moiety exerted better adjuvanticity than the MDP-C that has been reported by our laboratory previously. A primary scr
    Document: A series of new muramyl dipeptide (MDP) mimics were designed and synthesized via a solid-phase synthetic route. Their adjuvant activities were evaluated ex vivo for investigation of the synergism of the S(28–39) peptide, which is an MHC class I binding epitope of recombinant hepatitis B surface antigen (HBsAg) for both humans and mice. Several compounds without the carbohydrate moiety exerted better adjuvanticity than the MDP-C that has been reported by our laboratory previously. A primary screening test revealed that compounds 6, 14 and 16 exhibited stronger adjuvanticity compared with other MDP mimics.

    Search related documents:
    Co phrase search for related documents
    • absence presence and low toxicity: 1, 2
    • additional adjuvant and adjuvant activity: 1
    • liver cell and low toxicity: 1